We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Advisers Recommend Merck Insomnia Drug; Downplay Need for Additional Trials
FDA Advisers Recommend Merck Insomnia Drug; Downplay Need for Additional Trials
May 22, 2013
An FDA advisory committee Wednesday voted to recommend approval of Merck’s insomnia drug suvorexant, pointing to trial data showing the drug is effective in helping patients fall, and stay, asleep.